| Nome |
# |
|
Improving Adjuvant Endocrine Treatment Tailoring in Premenopausal Women With Hormone Receptor-Positive Breast Cancer, file e268c4cb-0e7d-a6b7-e053-3a05fe0adea1
|
338
|
|
State of the art on oocyte cryopreservation in female cancer patients: A critical review of the literature, file e268c4c8-5c3c-a6b7-e053-3a05fe0adea1
|
324
|
|
Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype, file e268c4c9-0e13-a6b7-e053-3a05fe0adea1
|
300
|
|
Dose-dense adjuvant chemotherapy in HER2-positive early breast cancer patients before and after the introduction of trastuzumab: exploratory analysis of the GIM2 trial, file e268c4cb-9528-a6b7-e053-3a05fe0adea1
|
202
|
|
Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis, file e268c4c9-0e18-a6b7-e053-3a05fe0adea1
|
176
|
|
Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials, file e268c4ca-4411-a6b7-e053-3a05fe0adea1
|
174
|
|
Reply to V. Turan et al, file e268c4c9-a94b-a6b7-e053-3a05fe0adea1
|
160
|
|
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years, file e268c4ca-690b-a6b7-e053-3a05fe0adea1
|
141
|
|
The association of financial difficulties with clinical outcomes in cancer patients: secondary analysis of 16 academic prospective clinical trials conducted in Italy, file e268c4c8-8f3e-a6b7-e053-3a05fe0adea1
|
140
|
|
Methods to Address Computed Tomography-Related Risk Factors in Oncology Patients: An Expert Opinion Based on Current Evidence, file e268c4c8-e63e-a6b7-e053-3a05fe0adea1
|
128
|
|
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer, file be0f987c-8f2d-4180-9b26-7f155395729e
|
122
|
|
Gonadotropin-releasing hormone analogs for ovarian function protection during chemotherapy in young early breast cancer patients: The last piece of the puzzle?, file e268c4c8-5b67-a6b7-e053-3a05fe0adea1
|
121
|
|
CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors, file e268c4c9-c85b-a6b7-e053-3a05fe0adea1
|
121
|
|
Weekly paclitaxel as first-line chemotherapy in elderly advanced breast cancer patients: a phase II study of the Gruppo Italiano di Oncologia Geriatrica (GIOGer), file e268c4c9-302d-a6b7-e053-3a05fe0adea1
|
117
|
|
Letrozole withdrawal response in locally advanced breast cancer, file e268c4c8-8a3f-a6b7-e053-3a05fe0adea1
|
112
|
|
Taxane-containing chemotherapy in the treatment of early breast cancer patients, file e268c4c9-27d1-a6b7-e053-3a05fe0adea1
|
111
|
|
Circulating tumor DNA analysis in breast cancer: Is it ready for prime-time?, file e268c4c9-cbe0-a6b7-e053-3a05fe0adea1
|
107
|
|
Single-agent PARP inhibitors for the treatment of patients with BRCA-mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis, file e268c4c9-0e11-a6b7-e053-3a05fe0adea1
|
105
|
|
Hormonal therapy followed by chemotherapy or the reverse sequence as first-line treatment of hormone-responsive, human epidermal growth factor receptor-2 negative metastatic breast cancer patients: Results of an observational study, file e268c4c8-5b04-a6b7-e053-3a05fe0adea1
|
104
|
|
Prevention of chemotherapy-induced menopause by temporary ovarian suppression with goserelin in young, early breast cancer patients., file e268c4c9-3016-a6b7-e053-3a05fe0adea1
|
103
|
|
Management of young women with early breast cancer, file e268c4c9-904a-a6b7-e053-3a05fe0adea1
|
102
|
|
Gonadotropin Releasing Hormone Agonists Have an Anti-apoptotic Effect on Cumulus Cells, file e268c4cb-a0df-a6b7-e053-3a05fe0adea1
|
100
|
|
An Italian Delphi study to evaluate consensus on adjuvant endocrine therapy in premenopausal patients with breast cancer: the ERA project, file e268c4c9-ef19-a6b7-e053-3a05fe0adea1
|
96
|
|
The PREgnancy and FERtility (PREFER) study: An Italian multicenter prospective cohort study on fertility preservation and pregnancy issues in young breast cancer patients, file e268c4c8-592b-a6b7-e053-3a05fe0adea1
|
95
|
|
Cancer and fertility preservation: international recommendations from an expert meeting, file e268c4c8-89f2-a6b7-e053-3a05fe0adea1
|
94
|
|
Analysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of Fc gamma RIIIA/Fc gamma RIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines, file e268c4c8-896f-a6b7-e053-3a05fe0adea1
|
85
|
|
Reply to the letter to the editor 'Can ovarian suppression with gonadotropin releasing hormone analogs (GnRHa) preserve fertility in cancer patients?' by Rodriguez-Wallberg et al., file e268c4ca-fad4-a6b7-e053-3a05fe0adea1
|
84
|
|
Inclusion of Platinum Agents in Neoadjuvant Chemotherapy Regimens for Triple-Negative Breast Cancer Patients: Development of GRADE (Grades of Recommendation, Assessment, Development and Evaluation) Recommendation by the Italian Association of Medical Oncology (AIOM), file e268c4ca-bef5-a6b7-e053-3a05fe0adea1
|
81
|
|
Erratum to: Analysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of FcγRIIIA/FcγRIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines, file e268c4ca-d661-a6b7-e053-3a05fe0adea1
|
75
|
|
Potential Mechanisms of Ovarian Protection with Gonadotropin-Releasing Hormone Agonist in Breast Cancer Patients: A Review, file e268c4ca-dbc5-a6b7-e053-3a05fe0adea1
|
73
|
|
New steps on an old path: Novel estrogen receptor inhibitors in breast cancer, file 549b0089-5116-4fb3-b672-02fa1ab99c28
|
43
|
|
Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies, file e268c4ce-ea12-a6b7-e053-3a05fe0adea1
|
30
|
|
null, file e268c4cd-d523-a6b7-e053-3a05fe0adea1
|
27
|
|
Safety of fertility preservation techniques before and after anticancer treatments in young women with breast cancer: a systematic review and meta-analysis, file e268c4ce-ae35-a6b7-e053-3a05fe0adea1
|
25
|
|
Adding a platinum agent to neoadjuvant chemotherapy for triple-negative breast cancer: the end of the debate, file e268c4ce-479b-a6b7-e053-3a05fe0adea1
|
22
|
|
Definition of High-Risk Early Hormone-Positive HER2−Negative Breast Cancer: A Consensus Review, file e268c4ce-abcd-a6b7-e053-3a05fe0adea1
|
19
|
|
Ovarian suppression using luteinizing hormonereleasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: A meta-analysis of randomized studies, file e268c4c6-d447-a6b7-e053-3a05fe0adea1
|
10
|
|
Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients, file e268c4c9-ef17-a6b7-e053-3a05fe0adea1
|
9
|
|
null, file e268c4ce-37fb-a6b7-e053-3a05fe0adea1
|
9
|
|
Plasma Cell-Free DNA Integrity Assessed by Automated Electrophoresis Predicts the Achievement of Pathologic Complete Response to Neoadjuvant Chemotherapy in Patients with Breast Cancer, file 1cf9eaf3-5b7b-46f0-acd9-81aa1ef82189
|
8
|
|
Effect of adjuvant chemotherapy with or without anthracyclines on the activity and efficacy of first-line cyclophosphamide, epidoxorubicin, and fluorouracil in patients with metastatic breast cancer, file e268c4cb-4845-a6b7-e053-3a05fe0adea1
|
8
|
|
Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer, file e268c4cb-4c56-a6b7-e053-3a05fe0adea1
|
8
|
|
Knowledge, attitudes and practice of physicians towards fertility and pregnancy-related issues in young BRCA-mutated breast cancer patients, file e268c4c9-dafa-a6b7-e053-3a05fe0adea1
|
7
|
|
Comparative effects of paclitaxel and docetaxel on the metabolism and pharmacokinetics of epirubicin in breast cancer patients, file e268c4cb-0407-a6b7-e053-3a05fe0adea1
|
7
|
|
Amenorrhea induced by adjuvant chemotherapy in early breast cancer patients: prognostic role and clinical implications, file e268c4cb-5b02-a6b7-e053-3a05fe0adea1
|
7
|
|
Cultural adaptation of the Italian version of the Patient-Reported Outcomes Common Terminology Criteria for Adverse Event (PRO-CTCAE®), file 2e490e6b-ac2b-43c4-afc8-316f36c60011
|
6
|
|
Optimal Adjuvant Chemotherapy Regimens for Patients With Early-Stage Breast Cancer, file e268c4c8-592e-a6b7-e053-3a05fe0adea1
|
6
|
|
Accelerated-intensified cyclophosphamide, epirubicin, and fluorouracil (CEF) compared with standard CEF in metastatic breast cancer patients: results of a multicenter, randomized phase III study of the Italian Gruppo Oncologico Nord-Ouest-Mammella Inter Gruppo Group, file e268c4cb-2bd7-a6b7-e053-3a05fe0adea1
|
6
|
|
Randomized phase III trial evaluating the role of erythropoietin in the prevention of chemotherapy-induced anemia, file e268c4cb-47d8-a6b7-e053-3a05fe0adea1
|
6
|
|
Effects of neoadjuvant trastuzumab, pertuzumab and palbociclib on Ki67 in HER2 and ER-positive breast cancer, file 3773a434-b076-41a9-aca4-9c298fc16840
|
5
|
|
null, file 815d5e27-dc92-4d12-a0ab-606075b93ef1
|
5
|
|
Role of fulvestrant in the treatment of postmenopausal metastatic breast cancer patients, file e268c4c8-8ec9-a6b7-e053-3a05fe0adea1
|
5
|
|
Immunotherapy for HER2-Positive Breast Cancer: Clinical Evidence and Future Perspectives, file b23c0551-f2d0-4442-aff9-b61f9b16b98e
|
4
|
|
Hormone Receptor/Human Epidermal Growth Factor Receptor 2-positive breast cancer: Where we are now and where we are going, file e268c4c8-6f4c-a6b7-e053-3a05fe0adea1
|
4
|
|
Pegfilgrastim administration after 24 or 72 or 96 h to allow dose-dense anthracycline- and taxane-based chemotherapy in breast cancer patients: a single-center experience within the GIM2 randomized phase III trial, file e268c4c8-8e35-a6b7-e053-3a05fe0adea1
|
4
|
|
Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 x 2 factorial, randomised phase 3 trial, file e268c4c8-8f41-a6b7-e053-3a05fe0adea1
|
4
|
|
The role of pneumatic compression in the treatment of postmastectomy lymphedema. A randomized phase III study, file e268c4cb-1f19-a6b7-e053-3a05fe0adea1
|
4
|
|
Single agent epirubicin as first line chemotherapy for metastatic breast cancer patients, file e268c4cb-238b-a6b7-e053-3a05fe0adea1
|
4
|
|
High dose intensity chemotherapy without bone marrow support: role of granulocyte-macrophage colony-stimulating factor, file e268c4cb-48c2-a6b7-e053-3a05fe0adea1
|
4
|
|
Luteininzing hormone releasing hormones analogs in combination with tamoxifen for the adjuvant treatment of premenopausal women with hormone receptor positive breast cancer, file e268c4c8-58ae-a6b7-e053-3a05fe0adea1
|
3
|
|
A case where switching end points for clinical trial interpretation might be the right choice, file e268c4c8-5bbf-a6b7-e053-3a05fe0adea1
|
3
|
|
Debated role of ovarian protection with gonadotropin-releasing hormone agonists during chemotherapy for preservation of ovarian function and fertility in women with cancer, file e268c4c8-5bfa-a6b7-e053-3a05fe0adea1
|
3
|
|
Patterns of Care and Clinical Outcomes of HER2-positive Metastatic Breast Cancer Patients With Newly Diagnosed Stage IV or Recurrent Disease Undergoing First-line Trastuzumab-based Therapy: A Multicenter Retrospective Cohort Study, file e268c4c8-5c00-a6b7-e053-3a05fe0adea1
|
3
|
|
Follow-up of patients with early breast cancer: Is it time to rewrite the story?, file e268c4c8-88b5-a6b7-e053-3a05fe0adea1
|
3
|
|
Temporary Ovarian Suppression With Gonadotropin-Releasing Hormone Agonist During Chemotherapy for Fertility Preservation: Toward the End of the Debate?, file e268c4c8-89d0-a6b7-e053-3a05fe0adea1
|
3
|
|
Progesterone receptor status and clinical outcome in breast cancer patients with estrogen receptor-positive locoregional recurrence, file e268c4c8-8fa0-a6b7-e053-3a05fe0adea1
|
3
|
|
ATAC trial update, file e268c4c9-2f4a-a6b7-e053-3a05fe0adea1
|
3
|
|
Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial, file e268c4ca-abca-a6b7-e053-3a05fe0adea1
|
3
|
|
Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial, file e268c4cb-1f17-a6b7-e053-3a05fe0adea1
|
3
|
|
Paradoxical effect of cytotoxic chemotherapy on anemia in cancer patients with beta-thalassemia minor, file e268c4cb-3779-a6b7-e053-3a05fe0adea1
|
3
|
|
Phase I, dose-finding study of capecitabine in combination with docetaxel and epirubicin as first-line chemotherapy for advanced breast cancer, file e268c4cb-47d4-a6b7-e053-3a05fe0adea1
|
3
|
|
Sequence effect of epirubicin and paclitaxel treatment on pharmacokinetics and toxicity, file e268c4cb-47dd-a6b7-e053-3a05fe0adea1
|
3
|
|
Identification of the highest dose of docetaxel associable with active doses of epirubicin. Results from a dose-finding study in advanced breast cancer patients, file e268c4cb-48c4-a6b7-e053-3a05fe0adea1
|
3
|
|
Impact of chemotherapy dose-density on radiotherapy dose-intensity after breast conserving surgery, file e268c4cb-48c6-a6b7-e053-3a05fe0adea1
|
3
|
|
Mitomycin C and mitoxantrone in anthracycline-pretreated advanced breast cancer patients. A phase II study, file e268c4cb-4a83-a6b7-e053-3a05fe0adea1
|
3
|
|
Influence of alternate sequences of epirubicin and docetaxel on the pharmacokinetic behaviour of both drugs in advanced breast cancer, file e268c4cb-4b18-a6b7-e053-3a05fe0adea1
|
3
|
|
Chemotherapy of non-small-cell lung cancer: role of erythropoietin in the management of anemia, file e268c4cb-5b0b-a6b7-e053-3a05fe0adea1
|
3
|
|
Assessing the Impact of the COVID-19 Outbreak on the Attitudes and Practice of Italian Oncologists Toward Breast Cancer Care and Related Research Activities, file e268c4cc-6a06-a6b7-e053-3a05fe0adea1
|
3
|
|
null, file e268c4cc-8809-a6b7-e053-3a05fe0adea1
|
3
|
|
Call for ensuring cancer care continuity during COVID-19 pandemic, file e268c4cc-a989-a6b7-e053-3a05fe0adea1
|
3
|
|
Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI), file e268c4cd-d013-a6b7-e053-3a05fe0adea1
|
3
|
|
The PREgnancy and FERtility (PREFER) Study Investigating the Need for Ovarian Function and/or Fertility Preservation Strategies in Premenopausal Women With Early Breast Cancer, file e268c4cd-ff7a-a6b7-e053-3a05fe0adea1
|
3
|
|
Cross-sectional study to develop and describe psychometric characteristics of a patient-reported instrument (PROFFIT) for measuring financial toxicity of cancer within a public healthcare system, file e268c4ce-7f87-a6b7-e053-3a05fe0adea1
|
3
|
|
Circulating miRNAs in Breast Cancer Diagnosis and Prognosis, file e268c4ce-b483-a6b7-e053-3a05fe0adea1
|
3
|
|
Influence of HER2 expression on prognosis in metastatic triple-negative breast cancer-results from an international, multicenter analysis coordinated by the AGMT Study Group, file 1407fe6b-fbc5-46ef-9b1c-df19241c5b8b
|
2
|
|
Adjuvant chemotherapy in breast cancer, file 1472e399-4022-4c5a-abc1-1114467f5820
|
2
|
|
Toxicity profile of antibody-drug conjugates in breast cancer: practical considerations, file 155f7dd0-46d6-4ada-ad0a-d18547f06f00
|
2
|
|
Sacituzumab Govitecan in HR-positive HER2-negative metastatic breast cancer, file 37c3482a-fc9f-47f1-8600-c9fcdbe39955
|
2
|
|
Concurrent vs Sequential Adjuvant Chemotherapy and Hormone Therapy in Breast Cancer: A Multicenter Randomized Phase III Trial, file e268c4c6-cbe2-a6b7-e053-3a05fe0adea1
|
2
|
|
Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: A pooled analysis of the MIG1 and GIM2 phase III studies, file e268c4c8-57c1-a6b7-e053-3a05fe0adea1
|
2
|
|
Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): An exploratory, open-label, phase 2 study, file e268c4c8-583c-a6b7-e053-3a05fe0adea1
|
2
|
|
Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in breast cancer patients, file e268c4c8-58bf-a6b7-e053-3a05fe0adea1
|
2
|
|
Risk of adverse events with the addition of targeted agents to endocrine therapy in patients with hormone receptor-positive metastatic breast cancer: A systematic review and meta-analysis, file e268c4c8-5c70-a6b7-e053-3a05fe0adea1
|
2
|
|
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial, file e268c4c8-6758-a6b7-e053-3a05fe0adea1
|
2
|
|
News on the medical treatment of young women with early-stage HER2-negative breast cancer, file e268c4c8-6d55-a6b7-e053-3a05fe0adea1
|
2
|
|
Medical approaches to preservation of fertility in female cancer patients, file e268c4c8-826d-a6b7-e053-3a05fe0adea1
|
2
|
|
5-Fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node-positive early breast cancer: a phase-III randomized GONO-MIG5 trial, file e268c4c8-835b-a6b7-e053-3a05fe0adea1
|
2
|
|
Everolimus-based therapy in patients with hormone receptor-positive, HER2(-) advanced breast cancer: management considerations, file e268c4c8-87c1-a6b7-e053-3a05fe0adea1
|
2
|
|
Targeting bone metastatic cancer: Role of the mTOR pathway, file e268c4c8-8848-a6b7-e053-3a05fe0adea1
|
2
|
|
The five "Ws" for bone pain due to the administration of granulocyte-colony stimulating factors (G-CSFs), file e268c4c8-88a7-a6b7-e053-3a05fe0adea1
|
2
|
| Totale |
4.504 |